Innovative Next Generation TCE Platform: INB-619 gamma-delta (γδ) TCE platform not only depletes its target CD19+ B cells, ...

Even after the pandemic, various new infectious diseases continue to emerge, posing ongoing viral threats that demand robust ...

Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell ...

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients ...

The withdrawal of immunosuppressants proves noninferior to the withdrawal of glucocorticoids and is safe in patients with ...

India's health statistics in 2021, including excess deaths, HDI rise, and improved mortality rates, analyzed and discussed ...